TareBio joins YC's summer batch with a cancer vaccine program
Physician-scientist Eta Atolia is turning years of neoantigen and synthetic-biology research into a Los Angeles biotech.
By Ryan Merket · Published
Primary source: X
Why it matters
TareBio pairs YC's company-building machinery with a physician-scientist whose research directly addresses one of cancer vaccines' hardest problems: choosing targets that produce a useful immune response.
TareBio has surfaced with a cancer vaccine program led by physician-scientist Eta Atolia (@eatolia), whose academic work has focused on tumor immunology, vaccine neoantigens and engineered cancer therapies.
https://x.com/eatolia/status/2084727101719265597
…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.